Simvastatin Augmentation of Lithium Treatment in Bipolar Depression
Status:
Terminated
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
Primary Aim: To estimate the antidepressant efficacy of simvastatin versus placebo as an
adjunct to lithium, valproate, and/or other atypical antipsychotic therapy among individuals
with bipolar I disorder in a nonpsychotic major depressive episode.
Hypothesis: Simvastatin will be superior to placebo in improvement of depressive symptoms
assessed by the Montgomery-Asberg Depression Rating Scale (MADRS).